How to Do Due Diligence on a Depression Treatment

You wouldn't put capital into a company because a friend said it was good. You'd want the numbers, the track record, the regulatory status, and the names behind it. You'd want to know what "success" means in their terms versus yours. And you'd be suspicious of anything that sounded too good, or that couldn't produce data on request.

For some reason, most people abandon that discipline when it comes to their own depression. They try what a doctor suggests, then what a friend suggests, then what an ad suggests, without ever asking the questions they'd ask about any other serious decision.

If you've been through several treatments that didn't work, and you're evaluating what comes next, this article gives you the framework. It applies to any option you're considering. We'll walk through it using SAINT as the worked example, because it's the treatment we offer and because it holds up.

This is the first filter, and it eliminates a surprising amount of what gets marketed to people with treatment-resistant depression. Retreats, IV protocols, supplements, off-label combinations, and "proprietary" methods often have no regulatory clearance at all, or clearance for something other than depression.

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) received FDA Breakthrough Device Designation and was cleared in 2022 specifically for adults with major depressive disorder who haven't gotten adequate relief from antidepressant medication in their current episode. That's the population you're in. That's the indication.

Track record matters. Was the treatment developed by a company with a product to sell, or by an academic institution with a research question?

SAINT was developed at Stanford's Brain Stimulation Lab by psychiatrists and neuroscientists studying why depression fails to respond to medication. It was published in peer-reviewed journals, replicated in a randomized controlled trial, and only then commercialized. The science came first.

This is where most treatments hide. "Improvement" and "response" are low bars; a 50 percent reduction in symptoms counts as response, and a person at 50 percent is still depressed. The number that matters is remission: symptoms reduced to the point where you no longer meet criteria for the illness.

In SAINT's clinical trials, 79 percent of participants reached remission. Not response. Remission. The average time to get there was 2.6 days. Across more than 400 trial patients, 85 percent experienced symptom relief.

For context, remission rates in similar treatment-resistant populations: another antidepressant trial, about 14 percent; esketamine, 16 to 37 percent; standard TMS, 17 to 32 percent; ECT, 48 percent. Ask any treatment you're evaluating for its remission rate in treatment-resistant patients, specifically. If they give you a response rate instead, or a number from a general population, note the substitution.

If you've failed three antidepressants, a fourth antidepressant is not diversification. It's the same bet with a different label. Every medication works on brain chemistry; that's the mechanism that's already come up short for you.

Depression is also a circuitry problem. The region behind the forehead that regulates mood, motivation, and attention is underactive, and its connections to the rest of the mood network are weakened. SAINT works on that circuit directly, using focused magnetic stimulation guided by an image of your own brain. It's a different mechanism, aimed at the layer your medications never reached.

Every serious evaluation asks what happens if it goes wrong. For medication, the downside is months of side effects for a low probability of remission. For ECT, it's anesthesia and a known risk of memory problems. For esketamine, it's dissociation, monitoring, and open-ended maintenance dosing.

For SAINT, the trials reported no serious adverse events across more than 400 patients. The most common side effects were mild headache, fatigue, and temporary scalp discomfort. Nothing enters your bloodstream, so there's no interaction with existing medications, which don't need to be stopped. It isn't appropriate for people with non-removable metal in or near the head or an implanted device.

Time is the resource that doesn't come back. A medication trial is six to twelve weeks to find out if it worked. Standard TMS is 30 to 36 daily visits over six to nine weeks. ECT is several weeks of sessions under anesthesia.

SAINT is five consecutive days: ten 10-minute sessions per day with 50-minute breaks between them, following a 45-minute fMRI and algorithm-driven targeting. Five clinic visits. One week.

A protocol is only as good as its execution. SAINT depends on precise imaging, correct targeting, and neuronavigation that keeps the coil on target for every session. That requires specific equipment and training, and Magnus Medical, the company that commercialized SAINT, designates providers who meet its standards as Verified SAINT Providers.

Neuro Wellness TMS Centers of America is a Verified SAINT Provider. Here's what the process looks like with us:

1. Consultation. Our clinical team reviews your full treatment history and confirms candidacy. We expect the history to be long. Bring it. The initial consultation is a Zoom call; as steps evolve, you'll also have the option to meet with our psychiatrist by Zoom web conference or in person. The mandatory in-person steps include fMRI mapping and the actual treatment.
2. fMRI brain scan. A roughly 45-minute functional MRI maps how your individual brain networks are wired.
3. Personalized targeting. The targeting algorithm reads your scan and identifies the exact stimulation point. Neuronavigation guides the coil there, session after session.
4. Five-day stimulation series. Ten sessions a day for five days, with a dedicated care team, in a private outpatient setting, with weekend availability if your schedule requires it.

Insurance coverage for SAINT is expanding but still varies by plan; some cover it with prior authorization, others don't yet. Self-pay is available. Our team will tell you exactly where you stand before anything is scheduled.

If you've already spent years and significant money on treatments that didn't work, the relevant question isn't whether SAINT costs more than a prescription. It's whether it's the best-evidenced option for the problem you actually have. On the questions above, it is.

The consultation is the due-diligence meeting. Bring your questions, bring your history, and expect straight answers, including "no" if SAINT isn't the right fit.

Schedule a consultation: 954-827-9793

If you are in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room. This article is for educational purposes and is not a substitute for individual medical advice.